Artificial nucleic acid molecules for improved protein expression

US11761009B2 · kind B2 · utility

Assignee

• CureVac SE · DE

Inventors

• Andreas Thess · Aspenhausiedlung, DE
• Thomas SCHLAKE · Gundelfingen, DE
• Stefanie GRUND · Stuttgart, DE

Key dates

• Filing date: Apr 5, 2022
• Grant date: Sep 19, 2023
• Expiry date: Apr 5, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to an artificial nucleic acid molecule or a vector comprising an open reading frame and a 3′-UTR comprising at least two poly(A) sequences. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.